Please login to the form below

Not currently logged in


This page shows the latest Reasanz news and features for those working in and with pharma, biotech and healthcare.

Novartis will file heart failure drug before year-end

Novartis will file heart failure drug before year-end

Novartis was less successful in its efforts to secure approval of acute heart failure therapy Reasanz (serelaxin), which was rejected by an FDA advisory committee earlier this year because of a ... Novartis is currently conducting a second phase III

Latest news

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....